Drug Database · Clinicians

Alfacalcidol + Minerals

Brands (1) AlfacalcinolShow all

Vitamin/Minerals PH FDA category
Fixed-dose combination.

Rx · Prescription drug1 PH product
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: Renal bone disease, hyperparathyroidism, hypoparathyroidism, rickets and osteomalacia (adults) renalcarematters.com, reviewed

    Kidney dosing: Alfacalcidol (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    No kidney dose adjustment: alfacalcidol is designed for impaired renal 1-alpha-hydroxylation. Start 1 microgram/day (0.5 microgram in older adults); usual maintenance 0.25 to 2 micrograms/day, titrated to calcium, phosphate, PTH and alkaline phosphatase (SmPC). Add a phosphate binder in renal bone disease.
    CrCl 30–59 mL/min
    KDIGO 2017: not for routine use in CKD G3a–G5 not on dialysis; reserve for severe, progressive secondary hyperparathyroidism (mainly G4–G5). If used: SmPC start 1 microgram/day (0.5 microgram in older adults), maintenance 0.25 to 2 micrograms/day, titrated to calcium, phosphate and PTH; stop for hypercalcemia.
    CrCl 15–29 mL/min
    KDIGO 2017: not for routine use in CKD G3a–G5 not on dialysis; reserve for severe, progressive secondary hyperparathyroidism (mainly G4–G5). If used: SmPC start 1 microgram/day (0.5 microgram in older adults), maintenance 0.25 to 2 micrograms/day, titrated to calcium, phosphate and PTH; stop for hypercalcemia.
    CrCl <15 mL/min (not on dialysis)
    KDIGO 2017: not for routine use in CKD G3a–G5 not on dialysis; reserve for severe, progressive secondary hyperparathyroidism (mainly G4–G5). If used: SmPC start 1 microgram/day (0.5 microgram in older adults), maintenance 0.25 to 2 micrograms/day, titrated to calcium, phosphate and PTH; stop for hypercalcemia.
    Hemodialysis (intermittent)
    Daily dosing as above, or intermittent dosing after each dialysis (2 to 3 times weekly): start 0.5 to 2 micrograms, adjust by 0.25 to 0.5 microgram steps by PTH, calcium and phosphate. Converting daily to intermittent: daily dose × 7/3 (three times weekly) or × 7/2 (twice weekly), rounded to 0.25 microgram (SmPC).
    Peritoneal dialysis
    Daily dosing titrated to calcium, phosphate and PTH (SmPC).
    CRRT
    No CRRT-specific guidance; usually held in acute illness. Specialist input.
    • Dialyzable? Not stated. In overdose, hemodialysis with low-calcium dialysate can treat hypercalcemia (SmPC 4.9).
    • Monitoring Serum calcium and phosphate regularly; PTH, alkaline phosphatase and calcium × phosphate product as indicated. If hypercalcemia occurs, stop until calcium normalizes (about 1 week), then restart at half the dose. Hypercalcemia can worsen kidney function and cause nephrocalcinosis (SmPC 4.4). In CKD, check calcium and phosphate often during titration and after each dose change, and PTH at the intervals in the KDIGO CKD-MBD guideline; prefer non-calcium phosphate binders if calcium is high-normal.

    From the Alfacalcidol monograph (renalcarematters.com, reviewed).

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Chewable tablet

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Alfacalcidol + Minerals as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Alfacalcidol + Minerals
Package insert
AlfacalcinolAlfacalcidol+ Minerals
(see reverse for formulation) Chewable TabletBlister Strip x 10’s (Box of 30’s)
Rx
Raptakos Brett & Co. Ltd.India
Raptakos Brett & Co. Ltd
DRP-1728
Nov 11, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .